1. In Vivo
  2. >>Leadership

Incyte Jumps Into Genome Mapping; Investors Jump out

Incyte Pharmaceuticals Inc. purchases Hexagen and creates a new business unit, Incyte Genetics, to be publicly traded as a tracking stock. Incyte Gentics' mission: to map the human genome within a year and generate SNP data for every human gene.

No sooner had Perkin-Elmer Corp. stepped up the human genome mapping race by joining efforts with The Institute for Genomic Research 's Craig Venter to form Celera Genomics Inc.[See Deal]. Incyte Genetics' mission: complete a map of the human genome within a year; create a large-scale genome sequence database; and generate single nucleotide polymorphism (SNP) data for every human gene. This poses a direct challenge to PE which, just months earlier, boasted that Celera would get the mapping job done in three years and thus beat the Human Genome Project's expected completion date of 2005.

Mark Bodmer, Hexagen's CEO and the newly named President of Incyte Genetics, argues that Incyte is ahead in the race...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By David Wild

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By Jo Shorthouse

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By Marion Webb

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

More from In Vivo

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By David Wild

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By Ian Taylor

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.

Deals Shaping The Industry, July 2025

An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.